Biotech Archives - Page 753 of 795

1 minute read

FDA Pushes Decision Date For Reata’s Genetic Neuromuscular Disease Candidate

August 9, 12:04 PM

The FDA has extended the review timeline for Reata Pharmaceuticals Inc’s (NASDAQ:RETA) marketing application seeking approval for omaveloxolone for Friedreich’s ataxia by…

RETA

1 minute read

Eagle Pharma Broadens Acute Care Portfolio With Equity Stake In Respiratory Depression Player

By Vandana Singh

August 9, 8:51 AM

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has agreed to make a $25 million equity investment in Enalare Therapeutics Inc. The investment consists of upfront…

EGRX

1 minute read

AstraZeneca’s Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients

By Vandana Singh

August 9, 8:43 AM

AstraZeneca Plc (NASDAQ:AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab…

AZN

2 minute read

Veru Highlights Presentation Of Phase 3 Study Of Sabizabulin At 11th International Conference on Emerging Infectious Diseases (ICEID) On August 7-10

By Bill Haddad

August 9, 8:33 AM

Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced

VERU

1 minute read

Verona Pharma’s Lung Disease Candidate Cuts COPD Exacerbations By 42%

By Vandana Singh

August 9, 7:39 AM

Verona Pharma plc (NASDAQ:VRNA) has announced topline results from Phase 3 ENHANCE-2 of nebulized ensifentrine for the maintenance treatment of chronic…

VRNA

1 minute read

FDA
News

Verona Pharma To Announce Top-Line Data From Phase 3 ENHANCE-2 Trial Of Nebulized Ensifentrine For COPD

By Benzinga Newsdesk

August 8, 5:46 PM

Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report top-line Phase 3 data from

VRNA

2 minute read

Why These Pfizer Analysts Like The Global Blood Therapeutics Deal

By Wayne Duggan

August 8, 2:50 PM

Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).

BHVN

1 minute read

Analyst Sees This ‘Specialty Pharma’ Stock Stuck Until Prescription Trends Improve

By Vandana Singh

August 8, 2:23 PM

Last week, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright…

COLL

1 minute read

Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications

By Vandana Singh

August 8, 2:09 PM

Sarepta Therapeutics Inc (NASDAQ:SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone…

SRPT

1 minute read

FDA
News

Kodiak Sciences Completes Enrollment In GLOW Phase 3 Clinical Trial Of Tarcocimab Tedromer (KSI-301) In Patients With Non-Proliferative Diabetic Retinopathy

By Benzinga Newsdesk

August 5, 4:31 PM

odiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has

KOD